Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal Antibody Drug Conjugates (ADC) Market, By Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), Product (Adcertis, Kadcyla, Others), Mechanism of Action (CD30 Antibodies, HER2 Antibodies), Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others), Indication (Lymphoma, Breast Cancer, Brain Tumor, Lung Cancer, Ovarian Cancer, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2030.
Antibody Drug Conjugates (ADC) Market Analysis and Size
The development of novel antibody technologies has contributed to the growth of the global Antibody Drug Conjugates (ADC) market. Antibodies with improved binding specificity, enhanced stability, and reduced immunogenicity are being developed, allowing for the creation of more effective ADCs. These advancements have expanded the potential applications of ADCs and increased their market demand.
Data Bridge Market Research analyzes that the global Antibody Drug Conjugates (ADC) market, which was USD 4,750.00 Million in 2022, would rocket up to USD 26,040.61 Million by 2030, and is expected to undergo a CAGR of 23.7% during the forecast period. “Antibody-Protein Toxin Conjugates” segment is expected to dominate the target segment of the market owing to the increasing investment in healthcare.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Antibody Drug Conjugates (ADC) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Year |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), Product (Adcertis, Kadcyla, Others), Mechanism of Action (CD30 Antibodies, HER2 Antibodies), Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others), Indication (Lymphoma, Breast Cancer, Brain Tumor, Lung Cancer, Ovarian Cancer, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) |
|
Countries Covered |
(U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of Middle East and Africa) |
|
Market Players Covered |
Seagen Inc. (U.S.), Genentech Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), F. Hoffmann-LA Roche Ltd. (Switzerland), Bristol -Myers Squibb (U.S.), Merck & Co., Inc. (U.S.), Immunomedics Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Onconova Therapeutics (U.S.), Helsinn Healthcare SA (Switzerland), Abbott (U.S.), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Private Limited (U.S.), DAIICHI SANKYO COMPANY, LIMITED. (Japan), and AbbVie Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
In the context of the market, ADCs are designed to selectively deliver potent drugs to cancer cells by attaching them to specific antibodies that recognize and bind to specific targets found on the surface of cancer cells. The antibody component of the ADC recognizes and binds to the cancer cell, allowing the cytotoxic drug payload to be delivered directly to the target cell. This targeted approach aims to minimize damage to healthy cells, reduce systemic toxicity, and enhance the therapeutic efficacy of the treatment.
Global Antibody Drug Conjugates (ADC) Market Dynamics
Drivers
- Increasing prevalence of cancer
The rising incidence of cancer worldwide is a significant driver for the ADC market. As the global burden of cancer continues to increase, there is a growing need for more effective and targeted treatment options.
- Advancements in antibody technology
Ongoing advancements in antibody engineering and conjugation technologies have facilitated the development of novel ADCs with improved efficacy, stability, and selectivity. These advancements have expanded the potential applications of ADCs and fueled market growth.
Opportunities
- Combination Therapies
ADCs can be combined with other therapeutic modalities, such as immunotherapies or targeted therapies, to create synergistic treatment approaches. Combination therapies offer the potential for improved outcomes and may open up new opportunities in the market.
Furthermore, the rising collaboration, merger, and acquisition among the market players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. In addition, the rising number of market players will further expand the market's growth rate in the future.
Restraints/Challenges
- High development costs
Developing ADCs requires significant investment in research and development, clinical trials, and regulatory approvals. The high development costs associated with ADCs pose a barrier to entry for smaller companies and may limit the development of novel ADC candidates.
On the other hand, the high cost associated with product manufacturing is expected to obstruct market growth. Also, the disruption in the supply chain industry, a lack of favorable reimbursement scenario and technology penetration in the developing economies, and lack of suitable infrastructure are projected to challenge the market growth in the forecast period of 2023-2030.
The global Antibody Drug Conjugates (ADC) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on this market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In 2021, Daiichi Sankyo received accelerated approval from the FDA for Enhertu (trastuzumab deruxtecan) for the treatment of locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
- In 2020, Pfizer received accelerated approval from the FDA for Trodelvy (sacituzumab govitecan-hziy) for the treatment of metastatic triple-negative breast cancer
Global Antibody Drug Conjugates (ADC) Market Scope
The global Antibody Drug Conjugates (ADC) market is segmented on the basis of target, product, mechanism of action, technology, indication, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Target
- Antibody-Protein Toxin Conjugates
- Antibody-Chelated Radionuclide Conjugates
- Antibody-Small-Molecule Drug Conjugates
- Antibody-Enzyme Conjugates
Product
- Adcertis
- Kadcyla
- Others
Mechanism of Action
- CD30 Antibodies
- HER2 Antibodies
Technology
- Immunogen Technology
- Seattle Genetics Technology
- Immunomedics Technology
- Others
Indication
- Lymphoma
- Breast Cancer
- Brain Tumor
- Lung Cancer
- Ovarian Cancer
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Global Antibody Drug Conjugates (ADC) Market Regional Analysis/Insights
The global Antibody Drug Conjugates (ADC) market is analyzed, and market size insights and trends are provided by target, product, mechanism of action, technology, indication, end-users, and distribution channel as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, and Rest of Middle East and Africa.
North America is expected to dominate the market due to factors including rising healthcare costs, increasing R&D activities, and trending technological advancements.
Asia-Pacific is expected to witness the fastest growth during the forecast period of 2023 to 2030 because of the rising strategic initiatives by the key market players and favorable government initiatives in the region.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global Antibody Drug Conjugates (ADC) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2021
Competitive Landscape and Global Antibody Drug Conjugates (ADC) Market Share Analysis
The global Antibody Drug Conjugates (ADC) market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global Antibody Drug Conjugates (ADC) market are:
- Seagen Inc. (U.S.)
- Genentech Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- F. Hoffmann-LA Roche Ltd. (Switzerland)
- Bristol -Myers Squibb (U.S.)
- Merck & Co., Inc. (U.S.)
- Immunomedics Inc.(U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Onconova Therapeutics (U.S.)
- Helsinn Healthcare SA (Switzerland)
- Abbott (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Johnson & Johnson Private Limited (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED. (Japan)
- AbbVie Inc. (U.S.)
SKU-
